Tag: aducanumab
A Win for Science, with Profound Implications for Industry: FDA Rejects...
Concerns, from functional unblinding to sexual assault in the clinical trials, led this week to a full repudiation of Lykos' MDMA-assisted therapy.
Pharma Corruption, Dangers of Antidepressants, And More
Peter Simons covers news on mental health app Cerebral and pharma companies Biogen and Cassava; how social media influencers are the new pharma marketers; studies that found antidepressants don't improve quality of life and are harmful to the fetus when pregnant women take them; benzo withdrawal; and more!
FDA Approves Failed Alzheimer’s Drug
The FDA approved Biogen's failed drug aducanumab, overriding the 10-0 recommendation of its own advisory committee. Three panel members resigned in protest.
Ethical Issues Raised Over FDA Collaboration with Biogen on Failed Drug
The FDA collaborated with Biogen to conduct repeated re-analyses of aducanumab for Alzheimer's and FDA committee members are raising concerns.
Biogen Pushes FDA to Approve Failed Alzheimer’s Drug
A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.
